title: Rapamycin, a potential disease-modifying antiarthritic drug.
abstract: Rapamycin (RAPA), a potent immunosuppressive agent that prevents organ graft rejection in animal models of transplantation, possesses a mechanism of action different than that of cyclosporin A and FK-506. In this study, the pharmacological activity of RAPA in a variety of immune and inflammatory models was assessed in order to define better its potential utility as an antiarthritic agent. RAPA inhibited T cell-mediated inflammation in mouse methylated bovine serum albumin-induced delayed-type hypersensitivity (ED40 = 4.7 mg/kg p.o.) and produced oral ED50 of 2.0 mg/kg against developing adjuvant arthritis in rats (3-day dosing schedule) and 9.5 mg/kg in established adjuvant arthritis in rats (daily dosing schedule). In both models of adjuvant arthritis, effects of RAPA were maintained even after cessation of drug dosing. In contrast, after discontinuation of cyclosporin A (5- and 10-mg/kg doses), disease activity returned. RAPA was also effective in another T cell-mediated model, experimental allergic encephalomyelitis (ED50 approximately 5 mg/kg p.o.). At higher doses, RAPA significantly inhibited carrageenan paw edema in rats, a model of acute inflammation (ED40, 56 mg/kg p.o.), without increasing serum corticosterone levels. In this model, doses approximately 10 to 20 times greater than active doses in T cell-mediated models were required. RAPA at 1 to 50 microM did not inhibit in vitro human synovial phospholipase A2 or 5-lipoxygenase and cyclo-oxygenase activity in the human blood leukocyte assay. The total profile of RAPA suggests that it may be effective in the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases.
authors.affiliation: Wyeth-Ayerst Research, Princeton, New Jersey.
authors.forename: R P
authors.initials: RP
authors.lastname: Carlson
authors.forename: D A
authors.initials: DA
authors.lastname: Hartman
authors.forename: L A
authors.initials: LA
authors.lastname: Tomchek
authors.forename: T L
authors.initials: TL
authors.lastname: Walter
authors.forename: J R
authors.initials: JR
authors.lastname: Lugay
authors.forename: W
authors.initials: W
authors.lastname: Calhoun
authors.forename: S N
authors.initials: SN
authors.lastname: Sehgal
authors.forename: J Y
authors.initials: JY
authors.lastname: Chang
mesh_terms: D000210:Acute-Phase Reaction / Q000517:prevention & control; D000818:Animals; D001169:Arthritis, Experimental / Q000517:prevention & control*; D015777:Eicosanoids / Q000378:metabolism; D006968:Hypersensitivity, Delayed / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D010741:Phospholipases A / Q000097:blood; D054467:Phospholipases A2; D011090:Polyenes / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew; D020123:Sirolimus
chemical_list: D015777:Eicosanoids; D007166:Immunosuppressive Agents; D011090:Polyenes; D010741:Phospholipases A; D054467:Phospholipases A2; D020123:Sirolimus